Castration-sensitive Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-sensitive Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-03-12Clinical Trial Update: PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer
This clinical trial investigates whether PSA biochemical response can serve as a prognostic factor in metastatic castration-sensitive prosta…
-
CLINICAL_TRIALS research · 2025-02-21Clinical Trial Update: Remotely Monitored Exercise Interventions in Patients with MCSPC Undergoing ADT (Prostate 006) [NA]
A clinical trial update describes a remotely monitored exercise intervention for men with castration-sensitive or metastatic prostate cancer…
-
CLINICAL_TRIALS trial_result · 2024-01-16Clinical Trial Update: TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer [Phase 3]
Phase 3 trial update for TAVT-45 (Abiraterone Acetate) granules in metastatic prostate cancer patients has completed with results posted.
-
FDA approval · 2023-12-19FDA Approved: ERLEADA — Supplemental Application (Janssen Products, LP)
The FDA approved a supplemental application for ERLEADA (apalutamide) filed by Janssen Products, LP. The approval updates the drug's labelin…
-
CLINICAL_TRIALS trial_result · 2023-10-26Clinical Trial Update: Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer [Phase 2]
A Phase 2 trial evaluating antiandrogen therapy (abiraterone acetate) with or without neutron radiation therapy in castration-sensitive/pros…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-03-23FDA Approved: ABIRATERONE ACETATE — Original Application (Florida Pharmaceutical Products, LLC)
FDA approved an abbreviated new drug application for a generic version of abiraterone acetate from Florida Pharmaceutical Products, LLC, for…
-
FDA approval · 2023-02-17FDA Approved: ERLEADA — Supplemental Application (Janssen Products, LP)
FDA approved a supplemental application for ERLEADA (apalutamide) submitted by Janssen Products, LP. The approval expands the drug's label f…
-
FDA approval · 2022-11-08FDA Approved: ERLEADA — Supplemental Application (Janssen Products, LP)
The FDA approved a supplemental application for Erleada (apalutamide) submitted by Janssen Products, LP.
-
FDA approval · 2022-04-26FDA Approved: ERLEADA — Supplemental Application (Janssen Products, LP)
The FDA approved a supplemental application for ERLEADA (apalutamide) filed by Janssen Products, LP.
-
CLINICAL_TRIALS trial_result · 2020-12-08Clinical Trial Update: Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan [Phase 4]
A Phase 4 trial update evaluating circulating tumor DNA in metastatic castration-sensitive prostate cancer patients in Japan treated with ap…
-
FDA approval · 2020-07-10FDA Approved: ERLEADA — Supplemental Application (Janssen Products, LP)
The FDA approved a supplemental application for ERLEADA (apalutamide) submitted by Janssen Products, LP, resulting in an expanded or updated…
-
CLINICAL_TRIALS trial_result · 2020-06-25Clinical Trial Update: Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer [Phase 2]
Phase 2 trial investigating docetaxel or abiraterone acetate with androgen deprivation therapy for metastatic hormone-sensitive prostate can…
-
FDA approval · 2018-02-14FDA Approved: ERLEADA — Original Application (Janssen Products, LP)
FDA approved ERLEADA (apalutamide) from Janssen Products, LP as the original NDA (NDA210951). It is approved for certain forms of prostate c…
-
FDA approval · 2015-03-20FDA Approved: ZYTIGA — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for ZYTIGA (abiraterone acetate) from Janssen Biotech, Inc.